Abstract:Ihuoma Eneli, 1, 2 Jinyu Xu, 1 Matthew Webster, 3 Amy McCagg, 3 Lex Van Der Ploeg, 3 Alastair S Garfield, 3 Elizabeth Estrada 4 1 Center for Healthy Weight and Nutrition, Nationwide Children's Hospital, Columbus, OH, USA; 2 Department of Pediatrics, The Ohio State University, Columbus, OH, USA; 3 Department of Medical Communications, Rhythm Pharmaceuticals, Inc, Boston, MA, USA; 4 Department of Pediatric Endocrinology, University of North Carolina, Chapel Hill, NC, USA Purpose: The hypothalamic melanocortin-4 receptor (MC4R) pathway, a component of the central melanocortin pathway, regulates energy balance and satiety. Rare genetic disorders of obesity may be characterized by impaired MC4R pathway signaling, which results in early-onset severe obesity and insatiable hunger (hyperphagia). The TEMPO registry (NCT03479437) is a voluntary, prospective, open-ended registry of individuals with rare genetic disorders of obesity due to mutations in genes within the MC4R pathway who have early-onset severe obesity. The objective of the TEMPO registry is to evaluate the burden of rare genetic disorders of obesity on individuals, their parents/caregivers, health care providers, and the health care system. Patients and methods: Individuals with rare genetic disorders of obesity (adults aged ≥18 years and children and adolescents aged from 2 to 17 years) will be referred by their health care providers or by a genetic screening study. Individuals must meet age- and sex-specific body mass index values that define the clinical criteria for severe obesity and carry selected variants in MC4R or in one of several genes upstream or downstream of the MC4R. Online surveys will be completed by the individual, parent/caregiver, and health care provider at baseline and annually thereafter and will collect data on demographics, results of genetic testing, medical/family history, disease characteristics, resource utilization, eating habits/hunger episodes, social and emotional impacts, and interest in future clinical trial participation. Conclusions: The TEMPO registry will provide insights into the overall course and disease burden for individuals with rare genetic disorders of obesity. Health care providers may use this resource to improve the identification, diagnosis, and treatment of individuals with rare forms of genetic obesity. Keywords: Alström syndrome, Bardet-Biedl syndrome, LEPR, PCSK1, POMC, severe obesity

Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment

Several Mutations in the Melanocortin 4 Receptor Gene Are Associated with Obesity in Chinese Children and Adolescents

Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R)

MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels

Functional Characterization of Novel MC4R Variants Identified in Two Unrelated Patients with Morbid Obesity in Qatar

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

Defect in MAPK Signaling As a Cause for Monogenic Obesity Caused by Inactivating Mutations in the Melanocortin-4 Receptor Gene.

A novel melanocortin 4 receptor (MC4R) gene mutation associated with morbid obesity

The genetic epidemiology of melanocortin 4 receptor variants

Tracing the effect of the melanocortin-4 receptor pathway in obesity: study design and methodology of the TEMPO registry

Impaired Coordination of Nutrient Intake and Substrate Oxidation in Melanocortin-4 Receptor Knockout Mice

Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach

Unexpected identification of obesity-associated mutations in LEP and MC4R genes in patients with anorexia nervosa

A human obesity-associated MC4R mutation with defective Gq/11α signaling leads to hyperphagia in mice

Homozygous null mutation of the melanocortin-4 receptor and severe early-onset obesity

A homozygous null mutation delineates the role of the melanocortin-4 receptor in humans

A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation

A Gut-Intrinsic Melanocortin Signaling Complex Augments L-Cell Secretion in Humans

Could setmelanotide be the game-changer for acquired hypothalamic obesity?

Divergence of melanocortin pathways in the control of food intake and energy expenditure.

Structural Complexity and Plasticity of Signaling Regulation at the Melanocortin-4 Receptor